Timed flat infusion of 5-fluorouracil increases the tolerability of 5-fluorouracil/docetaxel regimen in metastatic breast cancer: a dose-finding study

被引:3
作者
Ficorella, C
Morelli, MF
Ricevuto, E
Cannita, K
Porzio, G
Baldi, PL
Cianci, G
Di Rocco, ZC
Natoli, C
Tinari, N
De Galitiis, F
Calista, F
Marchetti, P
机构
[1] Univ Aquila, Dept Expt Med, I-67100 Laquila, Italy
[2] Univ Chieti, Dept Oncol & Neurosci, Sect Med Oncol, Chieti, Italy
关键词
breast cancer; docetaxel; 5-fluorouracil;
D O I
10.1038/sj.bjc.6601971
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
A dose-finding study was undertaken to determine the maximum-tolerated dose, and the recommended dose of docetaxel in combination with 12-h timed (22:00-10:00) flat infusion of 5-fluorouracil (5-FU) in metastatic breast cancer patients. This schedule seems to reduce the occurrence of stomatitis of the docetaxel and infusional 5-FU regimen.
引用
收藏
页码:618 / 620
页数:3
相关论文
共 50 条
  • [31] Continuous-infusion high-dose leucovorin with 5-fluorouracil and cisplatin for relapsed metastatic breast cancer: A phase II study
    Booser, DJ
    Walters, RS
    Holmes, FA
    Hortobagyi, GN
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2000, 23 (01): : 40 - 41
  • [32] Nocturnal 5-fluorouracil infusion to patients with breast cancer prior to surgery: Appearance of 5-fluorouracil-induced AgNORs aggregation (FAA)
    Furuya, Y
    Yamamoto, K
    Kohno, N
    Yamamoto, M
    Saitoh, Y
    CANCER LETTERS, 1997, 116 (01) : 79 - 84
  • [33] Phase II multicentre study of docetaxel plus 5-fluorouracil in patients with anthracycline-pretreated metastatic breast cancer
    Lortholary, A
    Delozier, T
    Monnier, A
    Bourgeois, H
    Bougnoux, P
    Tubiana-Mathieu, N
    Riffaud, JC
    Besson, D
    Lotz, V
    Gamelin, E
    BRITISH JOURNAL OF CANCER, 2003, 88 (11) : 1669 - 1674
  • [34] Phase II multicentre study of docetaxel plus 5-fluorouracil in patients with anthracycline-pretreated metastatic breast cancer
    A Lortholary
    T Delozier
    A Monnier
    H Bourgeois
    P Bougnoux
    N Tubiana-Mathieu
    J Ch Riffaud
    D Besson
    V Lotz
    E Gamelin
    British Journal of Cancer, 2003, 88 : 1669 - 1674
  • [35] Breast Cancer Resistance Protein Expression and 5-Fluorouracil Resistance
    JIAN-HUI YUAN*
    #Toxicology Laboratory
    ?Department of Emergency
    +Department of General Surgery
    BiomedicalandEnvironmentalSciences, 2008, (04) : 290 - 295
  • [36] Dose-intense PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) in advanced pancreatic adenocarcinoma:: A dose-finding study
    Reni, M.
    Cereda, S.
    Bonetto, E.
    Vigano, M. G.
    Passoni, P.
    Zerbi, A.
    Balzano, G.
    Nicoletti, R.
    Staudacher, C.
    Di Carlo, V.
    CANCER INVESTIGATION, 2007, 25 (07) : 594 - 598
  • [37] 5-fluorouracil encapsulated alginate beads for the treatment of breast cancer
    Arica, B
    Çalis, S
    Kas, HS
    Sargon, MF
    Hincal, AA
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2002, 242 (1-2) : 267 - 269
  • [38] Breast cancer resistance protein expression and 5-fluorouracil resistance
    Yuan, Jian-Hui
    Cheng, Jin-Quan
    Jiang, Long-Yuan
    Ji, Wei-Dong
    Guo, Liang-Feng
    Liu, Jian-Jun
    Xu, Xing-Yun
    He, Jing-Song
    Wang, Xian-Ming
    Zhuang, Zhi-Xiong
    BIOMEDICAL AND ENVIRONMENTAL SCIENCES, 2008, 21 (04) : 290 - 295
  • [39] Dose-finding study of weekly 24-h continuous infusion of 5-fluorouracil associated with alternating oxaliplatin or irinotecan in advanced colorectal cancer patients
    Cals, L
    Rixe, O
    François, E
    Favre, R
    Merad, L
    Deplanque, G
    Laadem, A
    Juin, P
    Bereder, JM
    Bernardini, D
    Herait, P
    ANNALS OF ONCOLOGY, 2004, 15 (07) : 1018 - 1024
  • [40] Polymorphism of thymidylate synthase gene and chemosensitivity of 5-fluorouracil regimen in metastatic gastrointestinal cancer
    Cui, Yue Hong
    Liu, Tian Shu
    Zhuang, Rong Yuan
    Gao, Hen Jun
    Li, Hong
    JOURNAL OF DIGESTIVE DISEASES, 2009, 10 (02) : 118 - 123